DDInter659 DDInter336
Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diflunisal
Diflunisal {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Celecoxib
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diflunisal
Diflunisal {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Celecoxib
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Levomilnacipran {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Celecoxib
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diflunisal
Diflunisal {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Celecoxib
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Celecoxib
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Celecoxib
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Celecoxib
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) ZMIZ1
ZMIZ1 {u} (Gene) is downregulated by {v} (Compound) Celecoxib
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Icosapent
Icosapent {u} (Compound) downregulates {v} (Gene) RBM34
RBM34 {u} (Gene) is downregulated by {v} (Compound) Celecoxib
Eptifibatide {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Anagrelide {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is palliated by {v} (Compound) Celecoxib
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Celecoxib (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Celecoxib (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Celecoxib (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Celecoxib (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Celecoxib (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Celecoxib (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Celecoxib (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates ZMIZ1 (Gene) and ZMIZ1 (Gene) is downregulated by Celecoxib (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Icosapent and Icosapent (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Celecoxib (Compound)
Eptifibatide may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is palliated by Celecoxib (Compound)